Andrea Pilotto

Oct 23, 2024 | onlinelibrary.wiley.com | Andrea Pilotto |Alice Galli |Cinzia Zatti |Fabio Placidi

Introduction Identifying in vivo markers that reflect risk for phenoconversion to clinically evident alpha-synucleinopathies remains an unmet need. Alpha-synucleinopathies include a spectrum of neurodegenerative disorders characterized by neuronal loss caused by the aggregation of misfolded α-synuclein protein leading to dopaminergic deficits.

May 3, 2024 | medrxiv.org | Andrea Pilotto |Oskar Hansson |Henrik Zetterberg |Virginia Quaresima

The authors have declared no competing interest. The research is supported by Airalzh Foundation AGYR2021 Life-Bio Grant, the Italian Ministry of University and Research PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast (20202THZAW), the Italian Ministry of Health, Grant/Award Number: RF-2018-12366209 and PNRR-Health PNRR-MAD-2022-12376110. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.